Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Myrobalan Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner within 1 distinct art unit. ANDERSON, REBECCA L is the busiest examiner for the portfolio, currently managing 1 pending office action.
With 1 pending matter, the prosecution strategy is entirely focused on a specific point of contact. Practitioners should prioritize understanding the requirements and historical trends of ANDERSON, REBECCA L to advance the application. The concentration of the current workload into 1 distinct art unit means that all efforts are subject to the examination standards of that particular unit.
Because the portfolio contains a limited number of pending matters, there are no other concurrent applications to leverage for comparison or internal benchmarking. Success in this technology area depends on a precise response to the individual examiner's feedback. The prosecution of this application represents the entirety of the company's current activity with the patent office, making the interaction with the assigned official critical for the portfolio's progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18874981 | CSF-1R INHIBITORS AND USES THEREOF | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874981 | CSF-1R INHIBITORS AND USES THEREOF | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | — | Pending | Dec 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMyrobalan Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rebecca L Anderson has the most, with 1 of Myrobalan Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
